Next generation allergen immunotherapy based on specifically modified recombinant hypoallergens

Project Information

AllergyVAX

Grant agreement ID: 829933

DOI

10.3030/829933

Project closed

EC signature date 25 October 2018

Start date 1 December 2018

End date 31 July 2021

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 3 684 750,00

EU contribution

€ 1 885 000,00

Coordinated by

DESENTUM OY
Finland

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (2)

Press release of the outcome of the clinical study
Final project report

Publications

Peer reviewed articles (1)

Development of hypoallergenic variants of the major horse allergen Equ c 1 for immunotherapy by rational structure based engineering

Author(s): Jaana Haka, Merja H. Niemi, Pekka Mattila, Janne Jänis, Kristiina Takkinen, Juha Rouvinen
Published in: Scientific Reports, Issue 9/1, 2019, ISSN 2045-2322
Publisher: Nature Publishing Group
DOI: 10.1038/s41598-019-56812-1

Intellectual Property Rights

Patent (2)

RECOMBINANT HYPOALLERGENIC EQU C 1 POLYPEPTIDES FOR USE IN THE IMMUNOTHERAPY OF HORSE ALLERGY

Application/Publication number: 20 19050002
Date: 2019-01-04
Applicant(s): DESENTUM OY

MODIFIED BETA-LACTOGLOBULINS FOR IMMUNOTHERAPY OF MILK ALLERGY

Application/Publication number: 09 765980
Date: 2009-06-18
Applicant(s): DESENTUM OY